Two top-10 investors in Moderna have voted against a shareholder resolution that would push the US drugmaker towards transferring its technology to the developing world.
The resolution, which will be proposed at the vaccine maker’s annual meeting on Thursday, asks its board of directors to explore the feasibility of transferring Moderna’s intellectual property and technical knowledge to help tackle “supply challenges” and facilitate the production of its mRNA Covid-19 vaccine in low- and middle-income countries.
One top-10 shareholder said: “We truly care about equitable access to vaccines but the key challenge is not supply of vaccines, it’s distribution.”
您已閱讀16%（665字），剩余84%（3522字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。